key: cord-0760263-8lu9al5l
authors: De Greef, Julien; Devresse, Arnaud; Albichr, Imane Saad; Scohy, Anais; Kanaan, Nada; Georgery, Hélène; Belkhir, Leila; Kabamba, Benoit; Yombi, Jean Cyr; Goffin, Eric
title: Better Late than Never: Eventual Seroconversion against SARS-CoV-2 in a Kidney Transplant Recipient after Repeated Immune Challenge and Monoclonal Antibody Therapy.
date: 2021-08-31
journal: Kidney Int
DOI: 10.1016/j.kint.2021.08.018
sha: fe30858501eb2d0b542c85566d0933cd1ccfb152
doc_id: 760263
cord_uid: 8lu9al5l

nan

Kidney transplant recipients (KTRs) are disproportionately affected by COVID-19. In addition to limited therapeutic options, concerns have arisen regarding poor vaccine efficacy in this population. 1 We report the case of a 64-year-old KTR treated with an association of tacrolimus, mycophenolate mofetil (MMF) and steroids who developed a second SARS-CoV-2 infection one year after a first COVID-19 episode, and 55 days after receiving his second BNT162b2-mRNA vaccine injection. Three days after the onset of isolated fever, high viral load of SARS-CoV-2 gamma variant was detected through RT-PCR in a nasopharyngeal swab (Table 1) . MMF was interrupted and intravenous monoclonal antibodies (casirivimab 1200mg and imdevimab 1200mg, Regeneron, USA) therapy was given. Clinical and virological evolutions were favorable: viral load decreased <1000 copies/mL on day 8 and was eventually negative on day 28 after perfusion (Table 1) . Interestingly, an anti-N native antibody seroconversion was observed on day 28 (Table 1) . Notably, three serologic tests had been performed before the second SARS-CoV-2 infection (including one 43 days after the second vaccine dose injection) and were all negative for both anti-N and anti-RBD antibody.

Anti-SARS-CoV-2 monoclonal antibodies have shown promising effects in COVID-19 2 , and preliminary results suggest efficacy in preventing severe disease after solid organ transplantation. 3 Our patient eventually mounted a natural immunity against SARS-CoV-2 in a context of repeated previous immune challenges and immunosuppression tapering. The effect of passive immunization on the development of protective immunity remains unknown. 4 Whether monoclonal antibodies infusion has promoted the development of natural immunity against SARS-CoV-2 remains to be investigated.

J o u r n a l P r e -p r o o f Day 0= day of monoclonal antibodies perfusion. Positivity thresholds: anti-N antibody ≥1, anti-RBD antibody ≥0.8 U/mL (upper detection limit of the assay: 250 U/mL).

Disappointing Immunization Rate after two Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients

Monoclonal Antibodies in Solid-Organ-Transplant Patients

Neutralizing monoclonal antibodies for treatment of COVID-19